Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 9 October 2026).

A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.